Esta página se tradujo automáticamente y no se garantiza la precisión de la traducción. por favor refiérase a versión inglesa para un texto fuente.

Evaluation of the Effect of a Seaweed Flour- and Leucine-Enriched Food on Metabolic and Inflammatory Status in Older Adults With Probable Sarcopenia or Sarcopenia

1 de julio de 2026 actualizado por: María Salomé Mariotti Celis, Finis Terrae University

Evaluation of the Effect of a Seaweed Flour- and Leucine-Enriched Food on Metabolic and Inflammatory Status in Older Adults With Probable Sarcopenia or Sarcopenia: A Prospective, Controlled, Randomized, Double-Blind, Three-Arm Parallel Clinical Trial

Sarcopenia and probable sarcopenia are associated with loss of muscle strength, functional impairment, frailty, and an increased risk of adverse outcomes in older adults. In short-term interventions, structural or functional changes may be modest, whereas certain serum biomarkers of metabolic-nutritional response may be more sensitive. In this protocol version, serum transthyretin (TTR) has been selected as the primary outcome, without assuming that it represents, by itself, a direct measure of muscle mass or overall clinical efficacy.

Descripción general del estudio

Descripción detallada

Sarcopenia is a progressive skeletal muscle disorder associated with aging and an increased risk of disability, hospitalization, dependency, and mortality. Contemporary consensus definitions identify low muscle strength as the primary characteristic of the condition, while muscle quantity or quality and physical performance are used to support the diagnosis and determine its severity.

In older adults, anabolic resistance reduces the muscle's responsiveness to habitual dietary protein intake. Leucine has been proposed as an amino acid capable of stimulating key anabolic pathways and therefore represents a plausible candidate for short-term nutritional interventions. In turn, Durvillaea incurvata flour provides bioactive compounds and dietary fiber with potential antioxidant and anti-inflammatory properties, although clinical evidence supporting its use in sarcopenia remains limited.

From a methodological perspective, a 28-day follow-up period may be sufficient to detect early metabolic and nutritional responses, but it may be insufficient to demonstrate robust clinical changes in muscle strength, muscle mass, or physical performance. For this reason, serum TTR has been selected as the primary short-term response outcome in the present protocol.

The selection of serum TTR as the primary outcome requires careful interpretation. Serum TTR levels may be influenced by protein-energy intake, liver function, inflammatory status, and intercurrent clinical conditions. Accordingly, in this protocol, serum TTR will not be interpreted as a direct surrogate of muscle mass or as a stand-alone measure of clinical efficacy. Rather, it will be considered a serum marker of early metabolic and nutritional response, whose interpretation will be complemented by functional, body composition, inflammatory, and safety-related outcomes.

This study is therefore designed as an exploratory, randomized proof-of-concept trial to determine whether the combination of leucine and seaweed flour improves serum TTR and whether this response is accompanied by consistent secondary changes in muscle strength, mobility, body composition, and the metabolic-inflammatory profile.

Tipo de estudio

Intervencionista

Inscripción (Estimado)

102

Fase

  • No aplica

Contactos y Ubicaciones

Esta sección proporciona los datos de contacto de quienes realizan el estudio e información sobre dónde se lleva a cabo este estudio.

Estudio Contacto

  • Nombre: María S Mariotti Celis, Ph D
  • Número de teléfono: +56 9 82332421
  • Correo electrónico: mmariotti@uft.cl

Ubicaciones de estudio

      • Santiago, Chile, 8010000
        • Universidad Finis Terrae
        • Contacto:
          • Cristian R Encina Acosta, Ph D
          • Número de teléfono: +56 9 62240100
          • Correo electrónico: cencinaa@uft.edu
        • Contacto:
          • Conrado S Camilo Manriquez
          • Número de teléfono: +56 9 77508471
          • Correo electrónico: ccamilo@uft.cl

Criterios de participación

Los investigadores buscan personas que se ajusten a una determinada descripción, denominada criterio de elegibilidad. Algunos ejemplos de estos criterios son el estado de salud general de una persona o tratamientos previos.

Criterio de elegibilidad

Edades elegibles para estudiar

  • Adulto
  • Adulto Mayor

Acepta Voluntarios Saludables

No

Descripción

Inclusion Criteria

  • Age between 60 and 80 years at the time of enrollment.
  • Ability to understand the study procedures and provide written informed consent.
  • SARC-F score ≥4 during screening.
  • Reduced muscle strength defined as handgrip strength <27 kg in men or <16 kg in women; alternatively, a time >15 seconds on the five-repetition chair stand test when handgrip dynamometry cannot be validly performed or is contraindicated.
  • Availability to attend study visits and comply with daily consumption of the study product for 28 days.
  • Willingness to provide fasting blood samples at the Day 0 and Day 28 visits. Exclusion Criteria
  • Cognitive impairment according to the abbreviated Mini-Mental State Examination (MMSE), using the operational cutoff approved for the study (≤13 points).
  • Clinically significant chronic liver disease, clinically significant chronic kidney disease, nephrotic syndrome, active cancer or recent oncological treatment, or any condition that may substantially affect serum TTR levels or increase participant risk.
  • Acute infection, acute inflammatory condition, or clinical decompensation at baseline that may interfere with the interpretation of serum TTR measurements.
  • Uncontrolled diabetes mellitus or any metabolic condition that, in the investigator's judgment, may increase the risks associated with the intervention.
  • Food allergy or intolerance to any component of the study product, including gluten, egg, milk, or other specific cake ingredients.
  • Use of leucine, HMB, or protein supplements within the previous 3 months.
  • Chronic use of systemic corticosteroids, immunosuppressive agents, or other therapies that may significantly alter the metabolic response under study.
  • Untreated thyroid disease or any other unstable endocrine disorder.
  • Clinically significant edema, severe dehydration, or any condition that may compromise the validity of bioelectrical impedance measurements.
  • Any medical, functional, social, or cognitive condition that may limit safe participation or adherence to the study protocol.

Plan de estudios

Esta sección proporciona detalles del plan de estudio, incluido cómo está diseñado el estudio y qué mide el estudio.

¿Cómo está diseñado el estudio?

Detalles de diseño

  • Propósito principal: Otro
  • Asignación: Aleatorizado
  • Modelo Intervencionista: Asignación paralela
  • Enmascaramiento: Triple

Armas e Intervenciones

Grupo de participantes/brazo
Intervención / Tratamiento
Comparador de placebos: Control chocolate cake
One daily serving of standard chocolate-flavored cake without added leucine or seaweed flour for 28 consecutive days
Participants will consume one standard chocolate-flavored cake serving daily for 28 days, without added leucine or seaweed flour.
Otros nombres:
  • Cake
Comparador activo: Leucine-enriched chocolate cake
One daily serving of standard chocolate-flavored cake supplemented with 3 g of leucine for 28 consecutive days
Participants will consume one chocolate-flavored cake serving supplemented with 3 g of leucine daily for 28 days.
Otros nombres:
  • Leucin
Experimental: Leucine and Durvillaea incurvata Flour-Enriched Chocolate Cake
One daily serving of standard chocolate-flavored cake supplemented with 3 g of leucine and 3 g of Durvillaea incurvata flour for 28 consecutive days.
Participants will consume one chocolate-flavored cake serving supplemented with 3 g of leucine and 3 g of Durvillaea incurvata flour daily for 28 days.
Otros nombres:
  • Seaweed

¿Qué mide el estudio?

Medidas de resultado primarias

Medida de resultado
Medida Descripción
Periodo de tiempo
Change from baseline in fasting serum transthyretin concentration at day 28.
Periodo de tiempo: 28 days
Fasting serum transthyretin (TTR; prealbumin) concentration (mg/dL) measured using Human Transthyretin/Prealbumin ELISA Kit (NBP2-60516, Bio-Techne, Novus Biologicals). The outcome is the change from Day 0 to Day 28 according to the Statistical Analysis Plan.
28 days

Medidas de resultado secundarias

Medida de resultado
Medida Descripción
Periodo de tiempo
Change from baseline in handgrip strength at day 28.
Periodo de tiempo: 28 days
Handgrip strength (kg) measured by dynamometry under standardized conditions. The operational measure, such as the best of three valid attempts.
28 days
Change from baseline in 4-meter gait speed at day 28.
Periodo de tiempo: 28 days
Usual gain speed (m/s) calculated from the 4-meter walk test under standardized condition.
28 days
Change from baseline in appendicular muscle mass index at day 28.
Periodo de tiempo: 28 days
Appendicular skeletal muscle mass index (kg/m2) measured calculated as appendicular skeletal muscle mass divided by height squared
28 days
Percentage (%) of prescribed study product serving consumed during the intervention.
Periodo de tiempo: 28 days
Adherence calculated from returned product counts and participant self-report as number of consumed servings divided by the number of prescribed servings.
28 days
Number of participants with adequate adherence during the intervention.
Periodo de tiempo: 28 days
Participants who consume at least 80% of prescribed study product serving during the 28-day intervention.
28 days

Otras medidas de resultado

Medida de resultado
Medida Descripción
Periodo de tiempo
Number of participants with any adverse event.
Periodo de tiempo: 28 days
Number of participants with at least one adverse event recorded from through the day 28 visit, regardless of relationship to the intervention.
28 days
Number of participants with serious adverse events.
Periodo de tiempo: 28 days
Number of participants with at least one serious adverse event, as defined by applicable ethical and regulatory criteria
28 days
Number of participants with treatment-related adverse events
Periodo de tiempo: 28 days
Number of participants with at least one adverse event assessed by the investigator as possibly, probably, or definitely related to the assigned study product.
28 days
Number of participants with gastrointestinal intolerance symptoms.
Periodo de tiempo: 28 days
Number of participants reporting gastrointestinal symptoms such as nausea, abdominal pain, bloating, diarrhea, constipation, vomiting, or other symptoms recorded in the tolerability form.
28 days
Number of participants who discontinue the study product due to an adverse event.
Periodo de tiempo: 28 days
Number of participants who permanently stop consuming the assigned study product because of an adverse event.
28 days
Change from baseline in serum TNF-alpha concentration at day 28.
Periodo de tiempo: 28 days
Fasting serum TNF-alpha concentration (pg/mL) measured using Human TNF-alpha ELISA Kit.
28 days
Change from baseline in serum OX-SR1 concentration
Periodo de tiempo: 28 days
Fasting serum OX-SR1 concentration (pg/mL) measured using Human Oxidative Stress Responsive (OXSR1) ELISA Kit
28 days
Change from baseline in fasting insulin concentration at day 28.
Periodo de tiempo: 28 days
Fasting serum insulin (uUI/mL) measure using the validated assay.
28 days
Change from baseline in total cholesterol concentration at day 28
Periodo de tiempo: 28 days
Fasting serum total cholesterol concentration (mg/dL) measured using the laboratory method.
28 days
Change from baseline in LDL cholesterol concentration at day 28.
Periodo de tiempo: 28 days
Fasting serum LDL cholesterol concentration (mg/dL) measured using the laboratory method.
28 days
Change from baseline in HDL cholesterol concentration at day 28.
Periodo de tiempo: 28 days
Fasting serum HDL cholesterol concentration (mg/dL) measured using the laboratory method.
28 days
Change from baseline in triglyceride concentration at day 28.
Periodo de tiempo: 28 days
Fasting serum triglyceride concentration (mg/dL) measured using the laboratory method.
28 days
Change from baseline in serum glucose concentration at day 28.
Periodo de tiempo: 28 days
Fasting serum glucose concentration (mg/dL) measured using the laboratory method
28 days
Change from baseline in serum total protein concentration at day 28.
Periodo de tiempo: 28 days
Fasting serum total protein concentration (mg/dL) measured using the laboratory method.
28 days
Change from baseline in serum total bilirubin concentration at day 28.
Periodo de tiempo: 28 days
Fasting serum total bilirubin concentration (U/L) measured using the laboratory method.
28 days
Change from baseline in serum albumin concentration at day 28.
Periodo de tiempo: 28 days
Fasting serum albumin concentration (g/dL) measured using the laboratory method.
28 days
Change from baseline in serum globulin concentration at day 28.
Periodo de tiempo: 28 days
Fasting serum globulin concentration (g/dL) measured using the laboratory method.
28 days

Colaboradores e Investigadores

Aquí es donde encontrará personas y organizaciones involucradas en este estudio.

Publicaciones y enlaces útiles

La persona responsable de ingresar información sobre el estudio proporciona voluntariamente estas publicaciones. Estos pueden ser sobre cualquier cosa relacionada con el estudio.

Publicaciones Generales

Fechas de registro del estudio

Estas fechas rastrean el progreso del registro del estudio y los envíos de resultados resumidos a ClinicalTrials.gov. Los registros del estudio y los resultados informados son revisados ​​por la Biblioteca Nacional de Medicina (NLM) para asegurarse de que cumplan con los estándares de control de calidad específicos antes de publicarlos en el sitio web público.

Fechas importantes del estudio

Inicio del estudio (Estimado)

1 de agosto de 2026

Finalización primaria (Estimado)

1 de octubre de 2026

Finalización del estudio (Estimado)

1 de marzo de 2027

Fechas de registro del estudio

Enviado por primera vez

18 de junio de 2026

Primero enviado que cumplió con los criterios de control de calidad

1 de julio de 2026

Publicado por primera vez (Actual)

8 de julio de 2026

Actualizaciones de registros de estudio

Última actualización publicada (Actual)

8 de julio de 2026

Última actualización enviada que cumplió con los criterios de control de calidad

1 de julio de 2026

Última verificación

1 de julio de 2026

Más información

Términos relacionados con este estudio

Plan de datos de participantes individuales (IPD)

¿Planea compartir datos de participantes individuales (IPD)?

NO

Información sobre medicamentos y dispositivos, documentos del estudio

Estudia un producto farmacéutico regulado por la FDA de EE. UU.

No

Estudia un producto de dispositivo regulado por la FDA de EE. UU.

No

Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .

Suscribir